LENVANAMO (Lenvatinib) is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment.
USES
- Certain types of advanced thyroid cancer
- Advanced Liver cancer
- Certain types of kidney cancer
- Endometrial cancer
GUARANTEE & EXPIRY DATE
100% original from SHIVNAAM TRADELINK LLP. Product photo may vary.
All packs are air tight sealed and expire up to 11.2026.
DESCRIPTION
Lenvanamo is an oral receptor tyrosine kinase inhibitor used in the treatment of thyroid cancer. Lenvanamo blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumour cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.
PACKAGING & DOSAGE
Comes in tablet form of varying strengths 4 mg or 10mg.
One pack contains 30 tablets.
Active ingredients: Lenvatinib mesylate (equivalent to Lenvatinib).
Excipients of the core: Mannitol, Microcrystalline Cellulose, Hydroxypropyl Cellulose, Low-Substituted Hydroxypropyl Cellulose, Magnesium Stearate.
The dosage of Lenvanamo varies depending on the type of cancer being treated and whether it is used alone or in combination with other therapies. It is typically taken orally once daily, with or without food.
Recommended Dosages by Cancer Type:
- Differentiated Thyroid Cancer: 24 mg once daily. Taken until disease progression or unacceptable toxicity.
- Hepatocellular Carcinoma (Advanced Liver Cancer): 12 mg once daily for patients weighing ≥60 kg (132 lbs). 8 mg once daily for patients weighing <60 kg (132 lbs).
- Renal Cell Carcinoma (Advanced Kidney Cancer): In combination with Everolimus: 18 mg of Lenvatinib once daily + 5 mg of Everolimus once daily. In combination with Pembrolizumab (Keytruda): 20 mg of Lenvatinib once daily + 200 mg of Pembrolizumab every 3 weeks.
- Endometrial Carcinoma: 20 mg once daily in combination with Pembrolizumab (200 mg IV every 3 weeks).
SIDE EFFECTS
The most common side effects of this medicine include tiredness, joint pain, muscle pain, nausea, and vomiting. It might also cause severe headache, confusion, problems with your eyesight, and difficult talking. If happens, your doctor may checked you for blood pressure as these might be symptom of high blood pressure. If you experience severe diarrhea, then consult with your doctor or drink plenty of fluids. Let your doctor know about severe abdominal pain or black, tarry, or bloody stools as it might be symptoms of bleeding disorder. You may be asked for some blood tests to check for liver, kidney, and level of thyroid stimulating hormones.
Before taking it, tell your doctor if have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding.
STORAGE
Store in dry place at room temperature. Do not exceed storage temperature higher than 25 degrees Celcius. Keep away from direct sunlight. Keep locked and away from children.
QUESTIONS?
Ask us any questions about Lenvanamo.
